Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with topline readout in 2Q24Company fully funded into 2025 with…

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis Read More

ARRALYZE(R) Launches CellShepherd(R): A Fully Autonomous Single-Cell Platform For Real-Time Monitoring Of Functional Assays

GARBSEN, GERMANY / ACCESSWIRE / February 5, 2024 / ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®. After a successful beta-testing phase in 2023, this groundbreakin…

ARRALYZE(R) Launches CellShepherd(R): A Fully Autonomous Single-Cell Platform For Real-Time Monitoring Of Functional Assays Read More

The Ohana Expands Its Reach: The Luxury Rehab Is Adding Capacity to Hawaii Location and Opening a California Location in 2024

LOS ANGELES, CA / ACCESSWIRE / February 5, 2024 / The Ohana, a world-class detox and residential inpatient treatment program, announces plans for expansion in 2024. In response to unprecedented demand for its services, The Ohana will be adding four add…

The Ohana Expands Its Reach: The Luxury Rehab Is Adding Capacity to Hawaii Location and Opening a California Location in 2024 Read More